Switching to Aflibercept 8 mg for wet AMD
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with wet (neovascular) age-related macular degeneration.
- You have been treated with eye injections (anti-VEGF drugs) for more than one year.
- You switched to aflibercept 8 mg before July 31, 2025.
- Before switching, you needed injections less than 12 weeks apart.
- You do not have severe nearsightedness, certain eye diseases, or diabetic eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with wet AMD who have been getting regular eye injections of either aflibercept or ranibizumab for over a year. The goal is to see what happens when they switch to a newer injection called faricimab.
This study tests whether switching to a higher dose of aflibercept (Eylea) is safe and effective for people with wet age-related macular degeneration who are already receiving standard-dose aflibercept. The goal is to see if the higher dose can better control the disease and possibly extend the time between injections.
This study looks at how well the higher-dose eye injection aflibercept 8 mg works in people who have already had at least three earlier anti-VEGF injections for wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). It tests if switching to this stronger dose is safe and effective in real-world care.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
Hear when a new Exudative Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.